Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature

Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2013, Pages 559-566

  Salem, Farzaneh ^a   Rostami Hodjegan, Amin ^a,b   Johnson, Trevor N ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Adults; Children; Drug drug interactions; Pediatrics; Pharmacodynamics; Pharmacokinetic and drug metabolism

Indexed keywords

AMIODARONE; ATOVAQUONE; AZITHROMYCIN; CARBAMAZEPINE; CHLORAMPHENICOL; CLONIDINE; CYCLOSPORIN; CYCLOSPORIN A; DIDANOSINE; DIGOXIN; ERYTHROMYCIN; ETOPOSIDE; IFOSFAMIDE; IMIPRAMINE; KETOCONAZOLE; LAMOTRIGINE; LIDOCAINE; MERCAPTOPURINE; METHOTREXATE; METHYLPHENIDATE; METHYLPREDNISOLONE; PHENYTOIN; PREDNISOLONE; PROPRANOLOL; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CHEMICAL INTERACTION; DRUG CLEARANCE; DRUG DRUG INTERACTION; DRUG EXPOSURE; DRUG INHIBITION; DRUG MONITORING; GESTATIONAL AGE; HUMAN; MEDICAL LITERATURE; MEDLINE; PHARMACODYNAMICS; PRACTICE GUIDELINE; SEIZURE; STEADY STATE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT; INFANT, NEWBORN; PHARMACOKINETICS;

EID: 84880179112     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.13     Document Type: Article

References (35)

1. Rostami-Hodjegan A, Tucker GT. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today Tech. 2004;1(4):441-448. (Pubitemid 40186348)
2. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet. 1969;2(7635):1397-1399.
3. Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Colburn WA, Bruck E. Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther. 1978;24(5): 571-575. (Pubitemid 9050951)
4. Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol. 1978;62(1): 27-29. (Pubitemid 8391444)
5. Saccar CL, Danish M, Ragni MC, et al. The effect of phenobarbital on theophylline disposition in children with asthma. J Allergy Clin Immunol. 1985;75(6):716-719. (Pubitemid 15002318)
6. Schneck DW, Luderer JR, Davis D, Vary J. Effects of nadolol and propranolol on plasma lidocaine clearance. Clin Pharmacol Ther 1984;36:584-587. (Pubitemid 15224660)
7. Conrad KA, Byers JM, Finley PR, Burnham L. Lidocaine elimination: effects of metoprolol and of propranolol. Clin Pharmacol Ther 1983;33:133-138. (Pubitemid 13093777)
8. Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit. 2002;24(5):598- 606.
9. Kuypers DR, Ekberg H, Grinyo J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009;48(5):329-341.
10. Gendrel D, Verdier F, Richard-Lenoble D, Nardou M. Interaction of cholestyramine and chloroquine. Arch Fr Pediatr. 1990;47(5):387- 388.
11. Belani CP, Kearns CM, Zuhowski EG, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-smallcell lung cancer. J Clin Oncol. 1999;17(2):676-684. (Pubitemid 29075257)
12. Danhof M, Mandema JW. Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs. Int J Clin Pharmacol Ther Toxicol. 1992;30(11):516-519. (Pubitemid 23001966)
13. van den Berg BTJ, DerksMGM, Koolen MGJ, Braat MCP, Butter JJ, van Boxtel CJ. Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. Pulm Pharmacol Ther. 1999;12(3): 185-192. (Pubitemid 29366419)
14. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010;70(1):78-87.
15. Zhao P, Vieira Mde L, Grillo JA, et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(1 Suppl): 91S-108S.
16. Orlando R, De Martin S, Pegoraro P, Quintieri L, Palatini P. Irreversible CYP3A inhibition accompanied by plasma proteinbinding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther. 2009; 85(3):319-326.
17. Collins C, Levy R, Ragueneau-Majlessi I, Hachad H. Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways. Curr Drug Metab. 2006;7(3):295-299.
18. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States JAMA. 2008;300(24):2867-2878.
19. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2010;21(3):291-301.
20. Delgado MR. Changes in valproic acid concentrations and dose/level ratios by felbamate coadministration in children. Ann Neurol. 1994;36(3):538-539.
21. Crocker JF, Renton KW, LeVatte TL, McLellan DH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol. 1994;8(4):408-411. (Pubitemid 24228627)
22. Committee for Human Medicinal Products, Guideline on the Investigation of Drug Interactions. 2010 European Medicines Agency.
23. Baxter K. Stockley's drug interactions. London: Pharmaceutical Press; 2010.
24. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther. 1987;42(4):424-432. (Pubitemid 17165704)
25. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit. 1999;21(2):182-190. (Pubitemid 29168896)
26. Kessler JM. Erythromycin-carbamazepine interaction. S Afr Med J. 1985;67: (26):1038.
27. Hoog-Labouret N. Clinical trials in children: guidance ICH E11, in: Jacqz-Aigrain E, Choonara I, editors. Paediatric clinical pharmacology. New York: Taylor and Francis. 2006.
28. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931-956. (Pubitemid 44299829)
29. Kandrotas RJ, Cranfield TL, Gal P, Ransom JL, Weaver RL. Effect of phenobarbital administration on theophylline clearance in premature neonates. Ther Drug Monit. 1990;12(2):139-143. (Pubitemid 20078593)
30. Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther. 1999;66(1):66-75. (Pubitemid 29350447)
31. Ngo LY, Yogev R, Dankner WM, et al. Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Antimicrob Agents Chemother. 1999;43(6):1516-1519. (Pubitemid 29259359)
32. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002; 41(12):959-998. (Pubitemid 35168438)
33. Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos. 2006;34(1):131-137. (Pubitemid 43042654)
34. Rostami-Hodjegan A. Physiologically-based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50-61.
35. Leong R, Vieira MLT, Zhoa P. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91:926-931.